{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Actinium_Ac_225_Lintuzumab",
  "nciThesaurus": {
    "casRegistry": "2209911-94-2",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A radioimmunoconjugate consisting of the humanized monoclonal antibody lintuzumab conjugated to the alpha-emitting radioisotope actinium Ac 225 with potential antineoplastic activity. The monoclonal antibody moiety of actinium Ac 225 lintuzumab specifically binds to the cell surface antigen CD33 antigen, delivering a cytotoxic dose of alpha radiation to cells expressing CD33. CD33 is a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on myeloid leukemia cells.",
    "fdaUniiCode": "V860J30J9N",
    "identifier": "C82414",
    "preferredName": "Actinium Ac 225 Lintuzumab",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C1511"
    ],
    "synonyms": [
      "225Ac-HuM195",
      "Actinium (225Ac) Lintuzumab Satetraxetan",
      "Actinium Ac 225 Lintuzumab",
      "Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195",
      "LINTUZUMAB SATETRAXETAN AC-225",
      "SGN-33 AC-225"
    ]
  }
}